HC Wainwright Lifts Earnings Estimates for Prime Medicine

Prime Medicine, Inc. (NYSE:PRME) – Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Prime Medicine in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.33). The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($1.19) EPS, FY2028 earnings at ($1.01) EPS, FY2029 earnings at ($0.82) EPS and FY2030 earnings at ($0.62) EPS.

Several other brokerages also recently weighed in on PRME. Citigroup decreased their target price on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Prime Medicine in a research report on Monday, November 10th. Chardan Capital reduced their price target on Prime Medicine from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 10th. Finally, Lifesci Capital started coverage on Prime Medicine in a report on Tuesday, December 23rd. They set an “outperform” rating and a $6.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.21.

Prime Medicine Trading Up 2.0%

Shares of Prime Medicine stock opened at $4.01 on Friday. The company has a fifty day moving average price of $3.83 and a 200 day moving average price of $4.17. Prime Medicine has a twelve month low of $1.11 and a twelve month high of $6.94. The stock has a market cap of $723.85 million, a price-to-earnings ratio of -1.96 and a beta of 2.56.

Hedge Funds Weigh In On Prime Medicine

Several large investors have recently modified their holdings of the stock. Alphabet Inc. lifted its position in shares of Prime Medicine by 10.0% during the third quarter. Alphabet Inc. now owns 16,562,498 shares of the company’s stock worth $91,756,000 after purchasing an additional 1,500,000 shares during the last quarter. ARK Investment Management LLC raised its stake in Prime Medicine by 135.8% during the third quarter. ARK Investment Management LLC now owns 5,477,851 shares of the company’s stock valued at $30,347,000 after buying an additional 3,155,182 shares in the last quarter. State Street Corp raised its stake in Prime Medicine by 293.0% during the fourth quarter. State Street Corp now owns 5,095,510 shares of the company’s stock valued at $17,681,000 after buying an additional 3,798,884 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Prime Medicine by 35.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company’s stock worth $27,267,000 after buying an additional 1,294,355 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its holdings in Prime Medicine by 533.3% during the 3rd quarter. Farallon Capital Management LLC now owns 4,750,000 shares of the company’s stock worth $26,315,000 after buying an additional 4,000,000 shares during the last quarter. Institutional investors own 70.37% of the company’s stock.

Key Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: HC Wainwright raised and tightened EPS forecasts across multiple quarters and years (Q1–Q4 2026 and FY2026–FY2030), cutting projected losses (e.g., FY2026 from ($1.39) to ($1.18) and improvements in FY2027–FY2029). That reduces near-term downside risk from operating losses and signals improving model expectations from a sell-side analyst. MarketBeat — HC Wainwright Estimates
• Positive Sentiment: Lifesci Capital published multiple quarterly and FY2026 estimates with a consistent “Outperform” rating and $6.00 price target, forecasting materially smaller losses for FY2026 (about ($0.90) vs. consensus deeper losses). A high target and repeated positive coverage can support demand for the shares. MarketBeat — Lifesci Capital Note
• Positive Sentiment: Analyst-aggregation coverage shows a favorable consensus (reported as an average “Moderate Buy”), reinforcing the bullish narrative from individual shops and likely contributing to buying interest. American Banking News — Analyst Rating

Prime Medicine Company Profile

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.